Allopurinol: Intravenous Use for Prevention and Treatment of Hyperuricemia

Smalley, Richard V.; Guaspari, A; Haase-Statz, Sandra; Anderson, Susan; Cederberg, D M; Hohneker, John

doi:10.1200/jco.2000.18.8.1758

Cited by 98 publications

(44 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, intravenous allopurinol was investigational at the time of initiation of study and was unavailable for comparison to rasburicase. 25 Future studies may want to compare the intravenous formulation of allopurinol to rasburicase.…”

Section: Discussionmentioning

confidence: 99%

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

Goldman

Holcenberg

Finklestein

et al. 2001

Blood

419

302

View full text Add to dashboard Cite

Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uric acid to a 5 times increased urine soluble product, allantoin. Rasburicase is a new recombinant form of urate oxidase available for clinical evaluation. This multicenter randomized trial compared allopurinol to rasburicase in pediatric patients with leukemia or lymphoma at high risk for tumor lysis. Patients received the assigned uric acid-lowering agent for 5 to 7 days during induction chemotherapy. The primary efficacy end point was to compare the area under the serial plasma uric acid concentration curves during the first 96 hours of therapy (AUC 0-96 ). Fifty-two patients were randomized at 6 sites. In an intent-to-treat analysis, the mean uric acid AUC 0-96 was 128 ؎ 70 mg/dL.hour for the rasburicase group and 329 ؎ 129 mg/dL.hour for the allopurinol group (P < .0001). The rasburicase versus allopurinol group experienced a 2.6-fold (95% CI: 2.0-3.4) less exposure to uric acid. Four hours after the first dose, patients randomized to rasburicase compared to allopurinol achieved an 86% versus 12% reduction (P < .0001) of initial plasma uric acid levels. No antirasburicase antibodies were detected at day 14. This randomized study demonstrated more rapid control and lower levels of plasma uric acid in patients at high risk for tumor lysis who received rasburicase compared to allopurinol. For pediatric patients with advanced stage lymphoma or high tumor burden leukemia, rasburicase is a safe and effective alternative to allopurinol during initial chemotherapy. (Blood. 2001; 97:2998-3003)

show abstract

Section: Discussionmentioning

confidence: 99%

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

Goldman

Holcenberg

Finklestein

et al. 2001

Blood

419

302

View full text Add to dashboard Cite

show abstract

“…40 Children responded rapidly with a mean response time of 1 day. However, adults responded slower with a mean response time of 5 days.…”

Section: Tls Treatment With Elitekmentioning

confidence: 99%

Elitek™–rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002

Larson

et al. 2003

Leukemia

View full text Add to dashboard Cite

“…An additional, important indication for the clinical use of allopurinol and possibly future XO inhibitors is tumor lysis syndrome associated with tumor chemotherapy (Maurer et al, 1988;Smalley et al, 2000). It is clear that in both indications, XO inhibition is very effective.…”

Section: A Xanthine Oxidase Inhibitors In the Treatment Of Gout And mentioning

confidence: 99%

Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol

2006

View full text Add to dashboard Cite

Allopurinol: Intravenous Use for Prevention and Treatment of Hyperuricemia

Abstract: IV allopurinol is as efficacious and safe as oral allopurinol and will be of significant benefit to patients at risk of TLS and AUAN and unable to take oral medication.

Cited by 98 publications

References 10 publications

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

Elitek™–rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002

Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol

Contact Info

Product

Resources

About